TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03947008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intuitive Eating Program
Description: A 5-week Intuitive Eating Curriculum created by a Registered Dietitian, Kaylee Frazier, will be used. The creator of this curriculum was contacted for permission and the curriculum was modified for use with college women.~The goal of the program is to challenge and eventually shift participant's mindset from the traditional diet culture towards a way of eating that is driven by their unique bodily needs. Content will focus on training participant to listen to their internal body cues for hunger opposed to restricting or eliminating foods. A list of intuitive eating principles and ways to incorporate them into daily routines will be provided to the participants throughout the sessions, coupled with homework assignments, journaling, and exercises to be completed before subsequent sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intuitive Eating Program
Description: A 5-week Intuitive Eating Curriculum created by a Registered Dietitian, Kaylee Frazier, will be used. The creator of this curriculum was contacted for permission and the curriculum was modified for use with college women.~The goal of the program is to challenge and eventually shift participant's mindset from the traditional diet culture towards a way of eating that is driven by their unique bodily needs. Content will focus on training participant to listen to their internal body cues for hunger opposed to restricting or eliminating foods. A list of intuitive eating principles and ways to incorporate them into daily routines will be provided to the participants throughout the sessions, coupled with homework assignments, journaling, and exercises to be completed before subsequent sessions.
Study: NCT03414528

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test
Description: Analysis of DNA samples of patients with molecularly undetermined PID by whole exome/genome sequencing Transcriptome analysis of patients with molecularly undetermined PID
Study: NCT01605682

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fresh berry extract.
Description: Fresh berry extract containing 500mg, 250mg, 125mg per 60 kilos of body weight. Or placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fresh berry extract.
Description: Fresh berry extract containing 500mg, 250mg, 125mg per 60 kilos of body weight. Or placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fresh berry extract.
Description: Fresh berry extract containing 500mg, 250mg, 125mg per 60 kilos of body weight. Or placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fresh berry extract.
Description: Fresh berry extract containing 500mg, 250mg, 125mg per 60 kilos of body weight. Or placebo.
Study: NCT01872481

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: rTMS in series of 20 trains of 6 s in duration (54-s intertrain interval) at a stimulation rate of 10 Hz (1200 pulses) at an intensity of 90% rest motor threshold. Sessions will be administered 5 days a week (Monday to Friday) during two consecutive weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham rTMS
Description: A coil with similar appearance to the active coil in shape and weight, producing a similar sound artifact but without emission of a magnetic pulse is used for the control group.
Study: NCT02997332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered every 3 weeks for 3 injections at week 1, 4, 7. Dose levels: the durvalumab first dose level is 1120 mg Q3W, and the dose level -1 is 750 mg Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m² on D2, IV in 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75mg/m² on D2, IV in 3 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Fluorouracil
Description: 5 Fluorouracil 750mg/m²/day on D2, D3, D4, D5, D6 IV in 24 hours
Study: NCT02023359

Intervention type: DRUG
Intervention: Everolimus and exemestane
Study: NCT01021709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS (Eldith DC-Stimulator (CE certified))
Description: tDCS session lasting continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm = 35 cm2 \& 10 x 10 cm = 100 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
Study: NCT02375451

Intervention type: OTHER
Intervention: Radioiodine
Description: We will determine if prior radioiodine treatment in childhood impacts salivary function or symptoms. Radioiodine treatment will have been determined by the patient's medical condition and care (NOT assigned by this research study).
Study: NCT03553381

Intervention type: OTHER
Intervention: hypocaloric balanced diet

Intervention type: OTHER
Intervention: hypocaloric balanced diet
Study: NCT04003766

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: biopsy
Description: Liver biopsy (LB) is essential for the diagnosis and evaluation of a variety of hepatic conditions, such as grading/staging of chronic liver disease secondary to alcohol, non-alcoholic steatohepatitis, viral hepatitis, hemochromatosis, Wilson's disease, cholestatic liver disease, as well as in elucidating the etiology of elevation in liver tests.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: biopsy
Description: Liver biopsy (LB) is essential for the diagnosis and evaluation of a variety of hepatic conditions, such as grading/staging of chronic liver disease secondary to alcohol, non-alcoholic steatohepatitis, viral hepatitis, hemochromatosis, Wilson's disease, cholestatic liver disease, as well as in elucidating the etiology of elevation in liver tests.
Study: NCT00517036

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA omega-3 fatty acid
Description: 1 gram per day of an EPA-enriched mixture for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA omega-3 fatty acid
Description: 1 gram per day of pure DHA for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: 1 gram per day of an inactive substance for 8 weeks
Study: NCT02263040

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High-Dose
Description: Influenza vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone (standard dose)
Description: Influenza vaccine
Study: NCT00416598

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Transplantation
Description: Undergo autologous bone marrow transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous PBSC transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01266746

Intervention type: PROCEDURE
Intervention: Vitreous surgery
Description: Vitreous surgery is performed to treat the original disease not for the study.

Intervention type: PROCEDURE
Intervention: Vitreous surgery
Description: Vitreous surgery is performed to treat the original disease not for the study.

Intervention type: PROCEDURE
Intervention: Vitreous surgery
Description: Vitreous surgery is performed to treat the original disease not for the study.
Study: NCT02781805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: 10 mg (1 tablet) once daily for 1-3 weeks before breast surgery; drug will be discontinued the day before surgery.
Study: NCT01613690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: NVA237 is administered via a BREEZHALER device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: NVA237 is administered via a BREEZHALER device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: NVA237 is administered via a BREEZHALER device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: NVA237 is administered via a BREEZHALER device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: NVA237 is administered via a BREEZHALER device
Study: NCT00848796

Intervention type: DRUG
Group type: OTHER
Intervention: Heparin Leo and Hepalean
Description: Dosage based on Heparin does response curve obtained from the Medtronic HMS plus
Study: NCT01509261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: 20mg/Tap, QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: 30mg/Tap, QD
Study: NCT03513744

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: human milk oligosaccharides
Description: mixture of five different human milk oligosaccharides
Study: NCT02646709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Low dose rocuronium (0.3 mg/kg) will be injected after induction of anesthesia with ketamine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Low dose rocuronium (0.3 mg/kg) will be injected after induction of anesthesia with ketamine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Low dose rocuronium (0.3 mg/kg) will be injected after induction of anesthesia with ketamine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine 1
Description: ketamine 1 mg/kg will be injected for induction of anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine 1.5
Description: ketamine 1.5 mg/kg will be injected for induction of anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine 2
Description: ketamine 2 mg/kg will be injected for induction of anesthesia
Study: NCT01546506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gutron® treatment
Description: Midodrine 2.5 mg orally 3 times daily, 5 day-treatment.
Study: NCT00676104

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CoolSystems Discrete Cerebral Hypothermia System
Description: The CoolSystems Discrete Cerebral Hypothermia System (DCHS) will be removed from the patients head after 48 hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoolSystems Discrete Cerebral Hypothermia System
Description: The CoolSystems Discrete Cerebral Hypothermia System (DCHS) will be removed from the patients head after 48 hours.
Study: NCT02422680

Intervention type: PROCEDURE
Intervention: No intervention, purely observational.
Description: No intervention is made other than following existing guidelines for colonoscopy. Further treatment and/or renewed colonoscopy in case of positive findings follows existing guidelines. The group is used only used to collect quality assurance data.
Study: NCT00475644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzastaurin
Description: Administered orally
Study: NCT01949181

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung surgery
Study: NCT03439358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Bolus infusion: 100mL normal saline with 4g MgSO4 over 30 minutes Maintenance infusion: 25mL normal saline per hour with 1g MgSO4

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Bolus infusion: 100mL normal saline over 30 minutes Maintenance infusion: 25mL normal saline per hour
Study: NCT04009031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bootle Blast
Description: During the baseline assessment, an occupational therapist will calibrate the video game to the child's therapy needs and functional abilities. Within a week of the first assessment, the research team will set up the video game in the participant's home where it will remain for 12 weeks. Training on how to play the game and a user manual will be provided. The researcher will work with each family to establish a play objective (minutes/day and days/week) that considers the family's schedule. Five-minute telephone check-in calls will be done weekly.
Study: NCT03740243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Description: Buprenorphine/naloxone tablet or film

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Buprenorphine tablet
Study: NCT02622399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project NOW
Description: This intervention aims to reduce social isolation and promote engagement in health promoting enrichment and activities, by embedding a community health worker-assisted forum in a community-driven mobile communications through a private, secure, and confidential platform supported by txtwire. The principal innovation is harnessing both the behavioral change utility of a mobile health application and the social support potential of an online social network the investigators can deliver more timely and dynamic reinforcement to caregivers and social support more in rhythm with the pace of community events and stressors.
Study: NCT02356705

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: midazolam 0.2 mg/kg given intranasally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: midazolam 0.2 mg/kg given intranasally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: xylocaine
Description: intransal xylocaine given in conjunction with intranasal midazolam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline placebo
Description: intranasal saline given as placebo
Study: NCT01131104

Intervention type: DRUG
Intervention: PDE5 Inhibitors
Description: Observational study of participants who have been prescribed phosphodiesterase type 5 (PDE5) inhibitors by their physician during routine clinical practice.
Study: NCT01762332

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Base level of remifentanil effect side concentration: 2ng/ml
Description: constant remifentanil level of 2ng/ml administered using Target Control Infusion pumps.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Base level of remifentanil effect side concentration: 4ng/ml
Description: constant remifentanil level of 4ng/ml administered using Target Control Infusion pumps.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chronic beta-blocker treatment
Description: Patients from the chronic beta-blocker treatment group will not be randomized, and will all be allocated to the high opioid level group.

Intervention type: OTHER
Group type: OTHER
Intervention: chronic beta-blocker treatment
Description: Patients from the chronic beta-blocker treatment group will not be randomized, and will all be allocated to the high opioid level group.
Study: NCT03024892

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG GB
Description: ICG was given by intra-gallbladder injection, then the near-infrared image guide laparoscopic cholecystectomy were performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG IV
Description: ICG was given by systemic injection, then the near-infrared image guide laparoscopic cholecystectomy were performed.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: LC conventional
Description: simple laparoscopic cholecystectomy was performed under white light image.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: LC conventional and IOC
Description: simple laparoscopic cholecystectomy was performed under white light image and intraoperaitve cholangiography guidance.
Study: NCT00304382

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: 0.5 ml IM into each deltoid muscle one time (or two in group PCV-PCV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: 0.5 ml IM into each deltoid muscle one time (or two in group PCV-PCV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: 0.5 ml IM into each deltoid muscle one time (or two in group PCV-PCV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: 0.5 ml IM into each deltoid muscle one time (or two in group PCV-PCV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax
Description: 0.5 ml IM one time

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax
Description: 0.5 ml IM one time
Study: NCT03038035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MLC901
Description: 24 weeks intervention with orally MLC901. 2 capsules 3 times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 24 weeks intervention with orally placebo. 2 capsules 3 times a day
Study: NCT00524186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Taken Orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative Study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative Study
Study: NCT03549091

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: transthoracic echocardiography
Description: This involves the acquisition of 1 additional sequence: a 10-minute sequence for transthoracic echocardiography.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiovascular Magnetic Resonance Imaging
Description: This involves the acquisition of 1 additional sequence: a 10-minute sequence for Cardiovascular Magnetic Resonance Imaging 4D Flow.
Study: NCT00507858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Starting dose of 500 mg/m\^2 IV Once Over 10 Minutes Every 3 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Starting dose of 500 mg/m\^2 IV Once Over 10 Minutes Every 3 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Starting dose of 500 mg/m\^2 IV Once Over 10 Minutes Every 3 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Arm 2 = 20 mg IV On Day 1; Arm 3 = 4 mg oral (PO) Twice Daily for 3 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Arm 2 = 20 mg IV On Day 1; Arm 3 = 4 mg oral (PO) Twice Daily for 3 Days
Study: NCT02209818

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Laser Irradiation One dose

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Laser Irradiation Two doses
Study: NCT04243226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telehealth-based aerobic walking exercise
Description: The aim of this study is to develop exercise prescription of TBI patients and then to evaluate the effectiveness of programmed aerobic exercise to improve psysical-psycho-social health such as cognitive status, 6 minutes walk test, depression relief, motivation, symptom, resilience and quality of life.
Study: NCT02918097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nortriptyline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Study: NCT04854941

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Probiotics (10\^9 CFU of each strain: Lactobacillus rhamnosus PDV 1705, Bifidobacterium bifidum PDV 0903, Bifidobacterium longum subsp. infantis PDV 1911 and Bifidobacterium longum PDV 2301) 3 times per day in addition to standard treatment regimen for 2 weeks
Study: NCT03153345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bedside respiratory muscle training
Description: The program consisted of three sessions: (1) 10 minutes of breath stacking exercise, followed by (2) 10 minutes of inspiratory muscle training using a flow-oriented incentive spirometer and (3) 10 minutes of expiratory muscle training using Acapella vibratory PEP device.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional stroke rehabilitation program
Description: The program consisted of joint range of motion exercises, muscle strengthening, gait training, fine motor exercises, and activity of daily living training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: conventional stroke rehabilitation program
Description: The program consisted of joint range of motion exercises, muscle strengthening, gait training, fine motor exercises, and activity of daily living training.
Study: NCT04645329

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shoulder immovilization sling
Description: immobilization of the arm after surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: shoulder immovilization sling
Description: immobilization of the arm after surgery
Study: NCT00743847

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects randomized to placebo will receive matching placebo and follow the titration schedule and dosing schedule of those randomized to varenicline.
Study: NCT01003119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Addiction CHESS
Description: Smartphone with ACHESS application loaded onto the phone.
Study: NCT00730015

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Oral, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Oral, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Oral, once daily
Study: NCT00580489

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: either fentanyl or morphine
Description: either morphine 4mg IV or fentanyl 50mcg IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: either fentanyl or morphine
Description: either morphine 4mg IV or fentanyl 50mcg IV